Inventiva S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVA.PA research report →
About the company
Inventiva S. A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments.
- CEO
- Andrew Obenshain
- IPO
- 2017
- Employees
- 114
- HQ
- Daix, FR
Price Chart
- Market Cap
- $432.48M
- P/E
- -1.64
- P/S
- 96.47
- P/B
- -69.47
- EV/EBITDA
- -2.95
- Div Yield
- 0.00%
- Gross Margin
- 35.07%
- Op Margin
- -3037.30%
- Net Margin
- -7899.58%
- ROE
- 1870.38%
- ROIC
- -66.18%
- Revenue
- $4.48M · -69.55%
- Net Income
- $-354,138,000 · -92.24%
- EPS
- $-1.90 · 38.31%
- Op Income
- $-136,327,000
- FCF YoY
- -21.88%
- 52W High
- $6.20
- 52W Low
- $2.56
- 50D MA
- $4.13
- 200D MA
- $4.38
- Beta
- 0.88
- Avg Volume
- 358.64K
Get TickerSpark's AI analysis on IVA.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IVA.PA coverage
Recent articles, reports, and earnings notes.
No research on IVA.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IVA.PA report →Similar companies
Peers in the same neighborhood.